Drugs / PACIBEKITUG
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01166555 | May → Oct 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00838565 | May 2009 → Feb 2012 | rheumatoid arthritis | Pfizer | Completed | No outcome recorded |
| Phase 25 trials · 1 missed | ||||||
| Phase 2 | NCT06362759 | May 2024 → Mar 2025 | chronic kidney disease | Tourmaline Bio, Inc., a Novartis Company | Completed | No outcome recorded |
| Phase 2 | NCT06088979 | Feb 2024 → Sep 2026 overdue | endocrine exophthalmos | Tourmaline Bio, Inc., a Novartis Company | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01405196 | Dec 2011 → Mar 2014 | systemic lupus erythematosus | Pfizer | Completed | Missed primary |
| Phase 2 | NCT01345318 | Jun 2011 → Mar 2016 | Crohn disease | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT01287897 | Feb 2011 → Sep 2014 | Crohn disease | Pfizer | Completed | Mixed |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-08-28 | Tourmaline Bio, Inc., a Novartis Company | Regulatory Tourmaline Bio Announces FDA Clearance of Investigational New Drug (IND) Application for TOUR006, an anti-IL-6 antibody with a differentiated profile for the treatment of thyroid eye disease (TED) tourmalinebio.com ↗
today announced U.S. Food and Drug Administration (FDA) clearance of Tourmaline’s IND application for TOUR006. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-09-09 | Novartis Pharmaceuticals | Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD) novartis.com ↗ |
| 2025-05-20 | Tourmaline Bio, Inc., a Novartis Company | Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease tourmalinebio.com ↗ |
| 2025-05-19 | Tourmaline Bio, Inc., a Novartis Company | Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025 tourmalinebio.com ↗ |
| 2023-08-28 | Tourmaline Bio, Inc., a Novartis Company | Tourmaline Bio Announces FDA Clearance of Investigational New Drug (IND) Application for TOUR006, an anti-IL-6 antibody with a differentiated profile for the treatment of thyroid eye disease (TED) tourmalinebio.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PACIBEKITUG | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068160 ↗ |
| Known as | PF 4236921 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068160 ↗ |
| Known as | PF-04236921 | “PF-04236921, a novel anti-interleukin-6 monoclonal antibody” PMID 29776017 ↗ Jun 2018 |
| Known as | TOUR006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06088979 ↗ |
| Action | Inhibit | “anti-interleukin-6 monoclonal antibody” PMID 29776017 ↗ Jun 20181“Interleukin-6 inhibitor” CHEMBL6068160 ↗ |
| Modality | Monoclonal antibody | “a novel anti-interleukin-6 monoclonal antibody” PMID 29776017 ↗ Jun 2018 |
| Route | Intravenous | “intravenous infusion” NCT00838565 ↗ |
| Target | IL6 | “Interleukin-6 inhibitor” CHEMBL6068160 ↗ |